Back to Course

2025 PACUPrep BCCCP Preparatory Course

0% Complete
0/0 Steps
  1. Pulmonary

    ARDS
    4 Topics
    |
    1 Quiz
  2. Asthma Exacerbation
    4 Topics
    |
    1 Quiz
  3. COPD Exacerbation
    4 Topics
    |
    1 Quiz
  4. Cystic Fibrosis
    6 Topics
    |
    1 Quiz
  5. Drug-Induced Pulmonary Diseases
    3 Topics
    |
    1 Quiz
  6. Mechanical Ventilation Pharmacotherapy
    5 Topics
    |
    1 Quiz
  7. Pleural Disorders
    5 Topics
    |
    1 Quiz
  8. Pulmonary Hypertension (Acute and Chronic severe pulmonary hypertension)
    5 Topics
    |
    1 Quiz
  9. Cardiology
    Acute Coronary Syndromes
    6 Topics
    |
    1 Quiz
  10. Atrial Fibrillation and Flutter
    6 Topics
    |
    1 Quiz
  11. Cardiogenic Shock
    4 Topics
    |
    1 Quiz
  12. Heart Failure
    7 Topics
    |
    1 Quiz
  13. Hypertensive Crises
    5 Topics
    |
    1 Quiz
  14. Ventricular Arrhythmias and Sudden Cardiac Death Prevention
    5 Topics
    |
    1 Quiz
  15. NEPHROLOGY
    Acute Kidney Injury (AKI)
    5 Topics
    |
    1 Quiz
  16. Contrast‐Induced Nephropathy
    5 Topics
    |
    1 Quiz
  17. Drug‐Induced Kidney Diseases
    5 Topics
    |
    1 Quiz
  18. Rhabdomyolysis
    5 Topics
    |
    1 Quiz
  19. Syndrome of Inappropriate Antidiuretic Hormone (SIADH)
    5 Topics
    |
    1 Quiz
  20. Renal Replacement Therapies (RRT)
    5 Topics
    |
    1 Quiz
  21. Neurology
    Status Epilepticus
    5 Topics
    |
    1 Quiz
  22. Acute Ischemic Stroke
    5 Topics
    |
    1 Quiz
  23. Subarachnoid Hemorrhage
    5 Topics
    |
    1 Quiz
  24. Spontaneous Intracerebral Hemorrhage
    5 Topics
    |
    1 Quiz
  25. Neuromonitoring Techniques
    5 Topics
    |
    1 Quiz
  26. Gastroenterology
    Acute Upper Gastrointestinal Bleeding
    5 Topics
    |
    1 Quiz
  27. Acute Lower Gastrointestinal Bleeding
    5 Topics
    |
    1 Quiz
  28. Acute Pancreatitis
    5 Topics
    |
    1 Quiz
  29. Enterocutaneous and Enteroatmospheric Fistulas
    5 Topics
    |
    1 Quiz
  30. Ileus and Acute Intestinal Pseudo-obstruction
    5 Topics
    |
    1 Quiz
  31. Abdominal Compartment Syndrome
    5 Topics
    |
    1 Quiz
  32. Hepatology
    Acute Liver Failure
    5 Topics
    |
    1 Quiz
  33. Portal Hypertension & Variceal Hemorrhage
    5 Topics
    |
    1 Quiz
  34. Hepatic Encephalopathy
    5 Topics
    |
    1 Quiz
  35. Ascites & Spontaneous Bacterial Peritonitis
    5 Topics
    |
    1 Quiz
  36. Hepatorenal Syndrome
    5 Topics
    |
    1 Quiz
  37. Drug-Induced Liver Injury
    5 Topics
    |
    1 Quiz
  38. Dermatology
    Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis
    5 Topics
    |
    1 Quiz
  39. Erythema multiforme
    5 Topics
    |
    1 Quiz
  40. Drug Reaction (or Rash) with Eosinophilia and Systemic Symptoms (DRESS)
    5 Topics
    |
    1 Quiz
  41. Immunology
    Transplant Immunology & Acute Rejection
    5 Topics
    |
    1 Quiz
  42. Solid Organ & Hematopoietic Transplant Pharmacotherapy
    5 Topics
    |
    1 Quiz
  43. Graft-Versus-Host Disease (GVHD)
    5 Topics
    |
    1 Quiz
  44. Hypersensitivity Reactions & Desensitization
    5 Topics
    |
    1 Quiz
  45. Biologic Immunotherapies & Cytokine Release Syndrome
    5 Topics
    |
    1 Quiz
  46. Endocrinology
    Relative Adrenal Insufficiency and Stress-Dose Steroid Therapy
    5 Topics
    |
    1 Quiz
  47. Hyperglycemic Crisis (DKA & HHS)
    5 Topics
    |
    1 Quiz
  48. Glycemic Control in the ICU
    5 Topics
    |
    1 Quiz
  49. Thyroid Emergencies: Thyroid Storm & Myxedema Coma
    5 Topics
    |
    1 Quiz
  50. Hematology
    Acute Venous Thromboembolism
    5 Topics
    |
    1 Quiz
  51. Drug-Induced Thrombocytopenia
    5 Topics
    |
    1 Quiz
  52. Anemia of Critical Illness
    5 Topics
    |
    1 Quiz
  53. Drug-Induced Hematologic Disorders
    5 Topics
    |
    1 Quiz
  54. Sickle Cell Crisis in the ICU
    5 Topics
    |
    1 Quiz
  55. Methemoglobinemia & Dyshemoglobinemias
    5 Topics
    |
    1 Quiz
  56. Toxicology
    Toxidrome Recognition and Initial Management
    5 Topics
    |
    1 Quiz
  57. Management of Acute Overdoses – Non-Cardiovascular Agents
    5 Topics
    |
    1 Quiz
  58. Management of Acute Overdoses – Cardiovascular Agents
    5 Topics
    |
    1 Quiz
  59. Toxic Alcohols and Small-Molecule Poisons
    5 Topics
    |
    1 Quiz
  60. Antidotes and Gastrointestinal Decontamination
    5 Topics
    |
    1 Quiz
  61. Extracorporeal Removal Techniques
    5 Topics
    |
    1 Quiz
  62. Withdrawal Syndromes in the ICU
    5 Topics
    |
    1 Quiz
  63. Infectious Diseases
    Sepsis and Septic Shock
    5 Topics
    |
    1 Quiz
  64. Pneumonia (CAP, HAP, VAP)
    5 Topics
    |
    1 Quiz
  65. Endocarditis
    5 Topics
    |
    1 Quiz
  66. CNS Infections
    5 Topics
    |
    1 Quiz
  67. Complicated Intra-abdominal Infections
    5 Topics
    |
    1 Quiz
  68. Antibiotic Stewardship & PK/PD
    5 Topics
    |
    1 Quiz
  69. Clostridioides difficile Infection
    5 Topics
    |
    1 Quiz
  70. Febrile Neutropenia & Immunocompromised Hosts
    5 Topics
    |
    1 Quiz
  71. Skin & Soft-Tissue Infections / Acute Osteomyelitis
    5 Topics
    |
    1 Quiz
  72. Urinary Tract and Catheter-related Infections
    5 Topics
    |
    1 Quiz
  73. Pandemic & Emerging Viral Infections
    5 Topics
    |
    1 Quiz
  74. Supportive Care (Pain, Agitation, Delirium, Immobility, Sleep)
    Pain Assessment and Analgesic Management
    5 Topics
    |
    1 Quiz
  75. Sedation and Agitation Management
    5 Topics
    |
    1 Quiz
  76. Delirium Prevention and Treatment
    5 Topics
    |
    1 Quiz
  77. Sleep Disturbance Management
    5 Topics
    |
    1 Quiz
  78. Immobility and Early Mobilization
    5 Topics
    |
    1 Quiz
  79. Oncologic Emergencies
    5 Topics
    |
    1 Quiz
  80. End-of-Life Care & Palliative Care
    Goals of Care & Advance Care Planning
    5 Topics
    |
    1 Quiz
  81. Pain Management & Opioid Therapy
    5 Topics
    |
    1 Quiz
  82. Dyspnea & Respiratory Symptom Management
    5 Topics
    |
    1 Quiz
  83. Sedation & Palliative Sedation
    5 Topics
    |
    1 Quiz
  84. Delirium Agitation & Anxiety
    5 Topics
    |
    1 Quiz
  85. Nausea, Vomiting & Gastrointestinal Symptoms
    5 Topics
    |
    1 Quiz
  86. Management of Secretions (Death Rattle)
    5 Topics
    |
    1 Quiz
  87. Fluids, Electrolytes, and Nutrition Management
    Intravenous Fluid Therapy and Resuscitation
    5 Topics
    |
    1 Quiz
  88. Acid–Base Disorders
    5 Topics
    |
    1 Quiz
  89. Sodium Homeostasis and Dysnatremias
    5 Topics
    |
    1 Quiz
  90. Potassium Disorders
    5 Topics
    |
    1 Quiz
  91. Calcium and Magnesium Abnormalities
    5 Topics
    |
    1 Quiz
  92. Phosphate and Trace Electrolyte Management
    5 Topics
    |
    1 Quiz
  93. Enteral Nutrition Support
    5 Topics
    |
    1 Quiz
  94. Parenteral Nutrition Support
    5 Topics
    |
    1 Quiz
  95. Refeeding Syndrome and Specialized Nutrition
    5 Topics
    |
    1 Quiz
  96. Trauma and Burns
    Initial Resuscitation and Fluid Management in Trauma
    5 Topics
    |
    1 Quiz
  97. Hemorrhagic Shock, Massive Transfusion, and Trauma‐Induced Coagulopathy
    5 Topics
    |
    1 Quiz
  98. Burns Pharmacotherapy
    5 Topics
    |
    1 Quiz
  99. Burn Wound Care
    5 Topics
    |
    1 Quiz
  100. Open Fracture Antibiotics
    5 Topics
    |
    1 Quiz

Participants 432

  • Allison Clemens
  • April
  • ababaabhay
  • achoi2392
  • adhoward1
Show more
Lesson 33, Topic 5
In Progress

Recovery, De-escalation, and Transition of Care After Variceal Hemorrhage

Lesson Progress
0% Complete
Recovery and Transition of Care After Variceal Hemorrhage

Recovery, De-escalation, and Transition of Care After Variceal Hemorrhage

Objectives Icon A checkmark inside a circle, symbolizing achieved goals.

Learning Objective

Facilitate safe recovery and handoff after acute variceal hemorrhage by providing step-by-step protocols for weaning vasoactive agents, converting to enteral therapy, preventing Post-ICU Syndrome (PICS), reconciling medications, and structuring discharge and follow-up.

1. Weaning and De-escalation of Intensive Therapies

After bleeding is controlled and hemodynamics stabilize, a structured taper of vasoactive infusions minimizes rebound portal hypertension and supports end-organ perfusion.

A. Hemodynamic Stability Criteria

The following criteria must be met for at least two consecutive assessments before initiating a wean:

  • Systolic blood pressure (SBP) ≥90 mm Hg without upward vasopressor adjustments
  • Heart rate (HR) 55–60 bpm at rest
  • Urine output >0.5 mL/kg/h
  • Serum lactate trending down
  • No new or worsening end-organ dysfunction (renal, hepatic, neurologic)

B. Protocol for Vasoactive Taper (Octreotide, Terlipressin)

Once stability is achieved, follow a systematic weaning process:

  1. Continue the full therapeutic infusion for 2–5 days after the index bleed is controlled.
  2. If stability is maintained, reduce the infusion rate by 25% every 4–6 hours.
  3. If any stability criteria are violated (e.g., SBP falls below 90 mm Hg), immediately return to the last tolerated rate and hold the wean. Reassess stability in 2 hours before attempting to resume the taper.
  4. Discontinue the infusion once the rate is less than 25% of the initial therapeutic dose and the patient remains stable.
Pearl Icon A shield with an exclamation mark, indicating a clinical pearl. Clinical Pearl: Advanced Monitoring During Wean

For high-risk patients, continue invasive arterial blood pressure monitoring throughout the wean. A central venous catheter can provide central venous oxygen saturation (ScvO₂) measurements. An early drop in ScvO₂ below 70% is a sensitive indicator of reduced oxygen delivery and predicts intolerance to the wean, often before hypotension occurs.

2. Transition from IV to Enteral Medications

Early initiation of oral nonselective β-blockers (NSBBs) is critical for secondary prophylaxis, supporting long-term portal pressure control and facilitating rehabilitation.

A. Assessing Gastrointestinal Readiness

Before starting oral medications, confirm:

  • Presence of bowel sounds and absence of clinical ileus.
  • Tolerance of small-volume enteral nutrition.
  • Patency of any enteral access tubes (nasogastric, nasojejunal, or gastrostomy) if the oral route is not yet feasible.

B. Nonselective β-Blocker (NSBB) Selection and Dosing

Selection and Titration of Nonselective β-Blockers
Agent Starting Dose Titration Target Clinical Notes
Propranolol 20 mg PO BID HR 55–60 bpm; SBP ≥90 mm Hg Lipophilic; undergoes extensive first-pass metabolism. Dose adjustments are often needed in severe hepatic impairment.
Nadolol 40 mg PO QD HR 55–60 bpm; SBP ≥90 mm Hg Primarily renally excreted. May be preferred if hepatic clearance is severely reduced, but requires dose adjustment in renal dysfunction.

C. Conversion Steps

  1. Begin the selected NSBB approximately 24 hours before the planned discontinuation of the vasoactive infusion to ensure overlap.
  2. Titrate the NSBB dose every 48 hours (e.g., by 10–20 mg of propranolol) based on heart rate and blood pressure response.
  3. Hold the NSBB dose and notify the provider if SBP drops below 90 mm Hg or resting HR is below 50 bpm.
Pitfall Icon A warning triangle with an exclamation mark, indicating a clinical pitfall. Clinical Pitfall: Ascites and Drug Absorption

Large-volume ascites significantly increases intra-abdominal pressure, which can compress the gut and impair the absorption of enteral medications. If a patient has tense or refractory ascites, prioritize medical management (diuretics, paracentesis) to reduce abdominal pressure before relying on oral therapies like NSBBs to be effective.

3. Prevention and Mitigation of Post-ICU Syndrome (PICS)

Survivors of critical illness, particularly variceal hemorrhage, are at high risk for PICS—a constellation of new or worsened cognitive, psychological, and physical impairments. Proactive, bundled strategies can reduce long-term morbidity.

A. Risk Factors for PICS

  • Mechanical ventilation >48 hours
  • Deep or prolonged sedation
  • ICU-acquired delirium
  • High illness severity (e.g., multiorgan failure, acute-on-chronic liver failure)

B. The ABCDEF Bundle

This multicomponent, evidence-based bundle is the standard of care for preventing PICS:

  • A: Assess, prevent, and manage pain
  • B: Both Spontaneous Awakening Trials (SATs) and Spontaneous Breathing Trials (SBTs)
  • C: Choice of analgesia and sedation to minimize delirium
  • D: Delirium: assess, prevent, and manage
  • E: Early mobility and exercise
  • F: Family engagement and empowerment

C. Early Mobilization Protocol

Once vasoactive infusions are discontinued and the patient is hemodynamically stable:

  1. Begin with passive range-of-motion exercises in bed.
  2. Progress to active range-of-motion and sitting at the edge of the bed.
  3. Collaborate with Physical and Occupational Therapy (PT/OT) to advance to standing, transferring to a chair, and ambulation as tolerated.

4. Comprehensive Medication Reconciliation

A pharmacist-led medication reconciliation at all care transitions (e.g., ICU to floor, hospital to home) is essential to avert medication errors, harmful duplications, and adverse drug interactions in this vulnerable population.

Medication Reconciliation Workflow A flowchart showing the four key steps of medication reconciliation: 1. Gather pre-admission and in-hospital medication lists. 2. Compare lists to confirm chronic therapies and identify discrepancies. 3. Resolve issues like duplications or high-risk drugs. 4. Document the final, verified list in the electronic health record. 1. GATHER Pre-admission & In-hospital Lists 2. COMPARE Confirm chronic therapies (NSBB) 3. RESOLVE Fix duplications & high-risk agents 4. DOCUMENT Final list in EHR
Figure 1: Pharmacist-Led Medication Reconciliation Workflow. This structured process ensures accuracy and safety at care transitions.
Pearl Icon A shield with an exclamation mark, indicating a clinical pearl. Clinical Pearl: Deprescribing High-Risk Medications

In patients with cirrhosis, long-term use of proton pump inhibitors (PPIs) and broad-spectrum antibiotics is associated with an increased risk of infections, including spontaneous bacterial peritonitis (SBP) and Clostridioides difficile. Actively review and discontinue these agents at discharge unless a clear, compelling indication remains (e.g., PPI for a documented ulcer).

5. Discharge Counseling and Handoff

Standardized patient education and clear communication with outpatient providers are proven strategies to reduce hospital readmissions and ensure continuity of care.

A. Patient and Caregiver Education

  • Medication Plan: Provide a clear NSBB titration schedule with explicit hold parameters (e.g., “Do not take your dose and call us if your top blood pressure number is less than 90 or your heart rate is less than 50”).
  • Nutritional Guidance: Recommend small, frequent, high-protein meals to combat sarcopenia. Provide guidance on sodium restriction if ascites or edema is present.
  • Warning Signs: Educate on signs of rebleeding (black or bloody stool, vomiting blood) or hypotension (dizziness, fainting) that warrant urgent medical evaluation.

B. Interdisciplinary Handoff

A structured handoff to the outpatient team is crucial. This should include:

  • Transmission of the fully reconciled medication list to the primary care provider, hepatologist, and outpatient pharmacist.
  • Clear documentation of vital sign targets (HR, SBP) and alert thresholds for NSBB therapy.
  • A summary of the hospital course, including endoscopic findings and interventions performed.

6. Long-Term Follow-Up Strategies

Ongoing surveillance and multidisciplinary support are necessary to prevent variceal recurrence, manage the progression of cirrhosis, and address late complications.

A. Surveillance Endoscopy

  • Initial Eradication: Repeat endoscopy with band ligation is typically performed every 2–4 weeks until all large varices are eradicated.
  • Long-Term Surveillance: After eradication, surveillance endoscopy is recommended every 6–12 months to monitor for recurrence. The interval may be individualized based on the initial variceal grade and other risk factors for decompensation.

B. Adherence and Side-Effect Monitoring

At every follow-up visit, the clinical team should:

  • Review NSBB adherence and address any barriers.
  • Actively screen for common side effects like dizziness, fatigue, and symptomatic hypotension.
  • Adjust the NSBB dose or hold therapy based on symptoms and measured vital signs.

C. Multidisciplinary Referrals

Ongoing care should involve a team approach:

  • Hepatology: For primary management of cirrhosis and variceal surveillance.
  • Nutrition/Dietetics: For ongoing dietary optimization to manage ascites and prevent malnutrition.
  • Physical/Occupational Therapy: To maintain muscle strength, improve function, and combat frailty.

References

  1. Kaplan DE, Ripoll C, Thiele M, et al. AASLD Practice Guidance on risk stratification and management of portal hypertension and varices in cirrhosis. Hepatology. 2024;79(4):1180–1211.
  2. Villanueva C, Albillos A, Genescà J, et al. β-blockers to prevent decompensation of cirrhosis in patients with CSPH (PREDESCI). Lancet. 2019;393(10181):1597–1608.
  3. Tsai MH, Huang HC, Peng YS, et al. Nutrition risk assessment using the modified NUTRIC score in cirrhotic patients with acute gastroesophageal variceal bleeding. Nutrients. 2019;11(9):2152.
  4. O’Leary JG, Reddy KR, Wong F, et al. Long-term use of antibiotics and proton pump inhibitors predict development of infections in patients with cirrhosis. Clin Gastroenterol Hepatol. 2015;13(4):753–759.e2.
  5. Garcia-Tsao G, Bosch J. Management of varices and variceal hemorrhage in cirrhosis. N Engl J Med. 2010;362(9):823–832.